Table 2. Comparisons of significant gene alteration frequency in GEPNEC and LNEC patients.

Gene	% (n/N)		OR (95% CI)	P	FDR
	GEPNEC	LNEC
GEPNEC, gastroenteropancreatic neuroendocrine carcinoma; LNEC, lung NEC; OR, odds ratio; 95% CI, 95% confidence interval; FDR, false discovery rate; Inf and −Inf, infinitive and −infinitive.
TP53 (mutation)	82.8 (82/99)	56.1 (32/57)	0.27 (0.12−0.59)	0.001	0.005
NKX2-1 (amplification)	0 (0/99)	10.5 (6/57)	Inf (2.17−Inf)	0.002	0.005
PIK3CA (amplification)	0 (0/99)	10.5 (6/57)	Inf (2.17−Inf)	0.002	0.005
KRAS (mutation)	21.2 (21/99)	3.5 (2/57)	0.14 (0.01−0.60)	0.002	0.005
TERT (amplification)	13.1 (13/99)	0 (0/57)	0 (0−0.52)	0.002	0.006
IL7R (amplification)	10.1 (10/99)	0 (0/57)	0 (0−0.73)	0.014	0.023
CTNNB1 (mutation)	16.2 (16/99)	3.5 (2/57)	0.19 (0.02−0.86)	0.019	0.027
GRIN2A (mutation)	1.0 (1/99)	8.8 (5/57)	9.29 (1.00−449.03)	0.025	0.028
PTPRD (mutation)	1.0 (1/99)	8.8 (5/57)	9.29 (1.00−449.03)	0.025	0.028
RB1 (mutation)	38.4 (38/99)	49.1 (28/57)	1.48 (0.95−8.46)	0.042	0.050